Oncotarget

Research Papers:

Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma

Hyunsoo Cho, Se Hoon Kim, Soo-Jeong Kim, Jong Hee Chang, Woo-Ick Yang, Chang-Ok Suh, Yu Ri Kim, Ji Eun Jang, June-Won Cheong, Yoo Hong Min and Jin Seok Kim _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:87317-87328. https://doi.org/10.18632/oncotarget.20264

Metrics: PDF 1610 views  |   HTML 2321 views  |   ?  


Abstract

Hyunsoo Cho1,2,*, Se Hoon Kim3,*, Soo-Jeong Kim1, Jong Hee Chang4, Woo-Ick Yang3, Chang-Ok Suh5, Yu Ri Kim1, Ji Eun Jang1, June-Won Cheong1, Yoo Hong Min1 and Jin Seok Kim1

1Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul 03722, Republic of Korea

2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic of Korea

3Department of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul 03722, Republic of Korea

4Department of Neurosurgery, Yonsei University College of Medicine, Severance Hospital, Seoul 03722, Republic of Korea

5Department of Radiation Oncology, Yonsei University College of Medicine, Severance Hospital, Seoul 03722, Republic of Korea

*These authors have contributed equally to this work

Correspondence to:

Jin Seok Kim, email: [email protected]

Keywords: primary central nervous system lymphoma, programmed cell death 1, programmed cell death-ligand 1, programmed cell death-ligand 2, prognosis

Received: June 12, 2017     Accepted: July 13, 2017     Published: August 14, 2017

ABSTRACT

Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under the receiver operating characteristic curve. Expression of PD-1, PD-L1, and PD-L2 was high in 7.9%, 13.2%, and 42.1% patients, respectively. High PD-1, (P = 0.007) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring (P = 0.019) were independently associated with inferior overall survival on multivariate analysis. High PD-1 also remained an independent prognostic factor for inferior progression-free survival (P = 0.028), as did MSKCC prognostic scoring (P = 0.041) on multivariate analysis. However, there were no differences in survival according to the expression levels of PD-L1/PD-L2 in PCNSL tumor microenvironment. Our results suggest that PD-1 may be considered a biomarker and potential therapeutic target in PCNSL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20264